Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $32.3 million versus the consensus estimate of $34.53 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c